In this study we intended to assess the serum tumor marker CA 15.3 among diabetic females in comparison to non diabetic females without neoplasia and any other diabetic complication. Results indicate that there is statically significance between diabetic and non-diabetic females, although the levels are within the normal range of method used. It reveals that serum tumor marker CA 15.3 is useful...

CA 15-3 is the most frequently used tumour marker in invasive breast cancer. Despite poor prognosis associated with an initially high value, scientific societies have not yet recommended its determination in the initial evaluation as regards the extent of disease [1–6]. Nevertheless, some institutions, such as the Henri-Becquerel Center (HBC), routinely include CA 15-3 determination before trea...

INVESTIGATION The concentrations of CA 15-3, TPA, and TPS were determined in the serum of 90 women with breast cancer MATERIAL/METHODS Serum CA 15-3 levels were determined by Abbott immunofluorescent tests, TPA concentration using the Byk-Roland immunoluminometric method, and TPS by the BEKI Diagnostics immunoenzymatic method. RESULTS In the diagnosis of breast cancer, the TPA test had the ...

A rare case of ovarian sarcoidosis with peritoneal and omental involvement presenting as an ovarian malignancy is presented. Clinical, laboratory, and radiological evaluation of the patient revealed ascites and high levels of serum CA 125 and CA 15.3. The diagnosis of sarcoidosis was confirmed with pathology findings on tissues obtained during surgical laparotomy. Establishing the diagnosis of ...

BACKGROUND CEA and CA 15.3 serum tumor markers are currently used in clinical practice for monitoring therapy. The aim of this study was to evaluate serum level of these markers among healthy females and invasive breast carcinoma (IBC) patients and to determine any relationships with clinicopathological factors. MATERIALS AND METHODS 60 Iranian females were enrolled in this study, 30 healthy ...

OBJECTIVE CA 15-3 is a traditional biomarker for advanced breast cancer with limited sensitivity for early stage patients. In order to increase the sensitivity for early detection, in this study, we introduced novel tumor-associated autoantibodies that were measured concurrently with serum CA 15-3 to evaluate their diagnostic advantage in breast cancer. METHODS We investigated a T7 breast can...

Background: Cancer Antigen 15-3, a derivative of a large transmembrane glycoprotein polymorphic epithelial mucin derived from MUC1 gene is a reliable marker in identifying patients who would benefit most from adjuvant therapy. Materials & Methods: Aimed at assessing the overall risk, possibility of distant metastasis and need for adjuvant therapy we assessed the role of pre-operative CA 15-3 an...